Stanley Erck, Advisor to the Board of Directors, Former CEO
Professional Overview
Stanley Erck is an experienced biotechnology executive with a proven track record of driving innovation and business growth. As an Advisor to the Board of Directors at Novavax and a Member of the Board of Directors at MaxCyte, Inc., he leverages his expertise in pharmaceutical development, strategic leadership, and corporate management to provide valuable counsel and oversight.
Experience Summary
Current Role
As Advisor to the Board of Directors at Novavax, Mr. Erck leverages his extensive industry knowledge and executive experience to guide the company's strategic decision-making. In this role, he collaborates with the board to establish and execute on Novavax's long-term vision, ensuring the company remains at the forefront of vaccine development and manufacturing.
Additionally, Mr. Erck serves as a Member of the Board of Directors at MaxCyte, Inc., a leading provider of cell engineering technologies. In this capacity, he contributes his insights and expertise to support the company's growth and innovation initiatives.
Career Progression
Prior to his current roles, Mr. Erck held several prominent leadership positions in the biotechnology industry. He served as the CEO of Iomai (now Intercell USA) from 2000 to 2008, where he led the company's successful development and commercialization of novel vaccine and immune-modulation technologies.
Earlier in his career, Mr. Erck held the role of CEO at PHT Corporation and Procept, where he demonstrated his ability to drive organizational growth and profitability. He also has significant experience in corporate development, having served as Vice President of Corporate Development at Integrated Genetics (now part of Genzyme Genetics).
Academic Background
Mr. Erck holds a Bachelor's degree, though the specific field of study is not provided in the background information.
Areas of Expertise
- Pharmaceutical and vaccine development
- Strategic leadership and corporate management
- Business development and commercialization
- Biotechnology industry expertise
- Board-level governance and advisory
Professional Impact
During his tenure as CEO of Iomai, Mr. Erck led the company's successful development and commercialization of innovative vaccine and immune-modulation technologies, positioning the company as a leader in the field. His contributions have had a significant impact on the biotechnology industry, particularly in the areas of vaccine development and immunotherapies.
Conclusion
With his extensive experience in the biotechnology industry, proven leadership skills, and deep expertise in vaccine development and corporate management, Stanley Erck continues to make valuable contributions to the companies he serves. As an Advisor to the Board of Directors at Novavax and a Member of the Board of Directors at MaxCyte, Inc., he is well-positioned to guide these organizations towards continued growth and innovation.
